GlassScriptPhysician profile
Russell Lee Walker
NPI 1871532184
$8,274.78
in general payments reported to CMS, 2019-2025
31 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,718 · 2020: $726 · 2021: $1,003 · 2022: $1,070 · 2023: $1,101 · 2024: $1,174 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,751 · Education: $7.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,750.68 |
| Education | $7.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,048.21 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,354.25 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $1,008.10 | 2019-2025 | Haegarda, Andembry |
| Genzyme Corporation | $630.64 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $580.47 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $511.00 | 2019-2025 | Dupixent |
| Pfizer INC. | $413.73 | 2019-2025 | |
| Genentech USA, INC. | $313.23 | 2019-2025 | Xolair |
| Kaleo, INC. | $261.23 | 2019-2024 | Auvi-Q |
| Alk-Abello, INC | $168.66 | 2019-2022 | |
| Optinose US, INC. | $128.10 | 2021-2025 | |
| Ars Pharmaceuticals Operations, INC. | $117.30 | 2025 | Neffy |
| Blueprint Medicines Corporation | $102.78 | 2022-2025 | Ayvakit |
| Grifols USA, LLC | $89.88 | 2021-2025 | Xembify |
| Cycle Pharmaceuticals INC | $78.94 | 2025 | Sajazir |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $54.45 | 2019-2021 | |
| Octapharma USA, INC. | $46.20 | 2024-2025 | Cutaquig |
| Ionis Pharmaceuticals, INC. | $41.48 | 2025 | Dawnzera |
| Mylan Specialty L.P. | $41.26 | 2019 | |
| Merck Sharp & Dohme LLC | $34.82 | 2021-2023 | |
| Shire North American Group INC | $33.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.16 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.63 | 2019 | |
| Phadia US INC. | $24.18 | 2024 | Immunocap |
| Hikma Pharmaceuticals USA | $23.76 | 2023 | Ryaltris |
| Sunovion Pharmaceuticals INC. | $21.69 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $21.13 | 2020 | |
| Incyte Corporation | $19.67 | 2025 | Opzelura |
| Aimmune Therapeutics, INC. | $18.23 | 2021 | |
| Pharming Healthcare, INC. | $17.81 | 2019 | |
| Lilly USA, LLC | $14.38 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.